RICHMOND, Calif., Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioAge Labs (Nasdaq: BIOA) (“BioAge”, “the Company”), a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will participate in the following upcoming investor conferences:
Read the rest here:
BioAge Labs to Present at Upcoming Investor Conferences
NEW HAVEN, Conn., Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (the “Company”) (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it has commenced an underwritten public offering of shares of its common stock, par value $0.001 per share (“Common Stock”), and accompanying warrants to purchase shares of Common Stock, and, in lieu thereof to certain investors that so choose, pre-funded warrants to purchase shares of Common Stock and accompanying warrants to purchase shares of Common Stock.
Go here to read the rest:
BioXcel Therapeutics Announces Proposed Public Offering
Ad Hoc Announcement Pursuant to Art. 53 LR
See the original post here:
Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
— Launch follows approval by Japanese Ministry of Health, Labour and Welfare in September 2024 —
More:
HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan
LAS VEGAS, Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioAdaptives Inc. (OTC: BDPT) ushered in a new direction by appointing James Keener as CEO on May 21, 2024. Previous management retired, and Keener began focusing on products that are in demand and can change people's lives.
Read the original:
BioAdaptives, Inc. Announces 5 Unique Products Ready for Phased Entry Into the Nutritional Marketplace
Orion Research Foundation grants EUR 1,109,000 for research in 2025
The rest is here:
Orion Research Foundation grants EUR 1,109,000 for research in 2025
First and only NMPA-approved treatment for patients with CIDP in China
Read the rest here:
argenx and Zai Lab Announce Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy in China
Claims about Rolvedon and Assertio’s Accounting Practices are False and Baseless
More here:
Assertio Provides Response to Letter from Short-seller
TORONTO, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that patient recruitment and dosing have begun in Canada for the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI).